Editor’s Choice

Editor's Choice

Ferring and Rebiotix Present Landmark Phase 3 Data

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) […]

In Case you Missed it:

Editor's Choice

Ferring and Rebiotix Present Landmark Phase 3 Data

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) […]

Sign up to Free Newsletter

Microbiome-based Diagnostics & Biomarkers: Free Market Report

The Microbiome Drug Database

Advertisements